235876 Finsbury WWH pp23-pp29new 03 07 2015 12:33 Page 25 2 Governance Report of the Directors The Directors present their annual report on the affairs of ex income NAV per share at the time of issue, resulting in a the Company together with the audited financial statements net gain to the Company of 160,000. and the Independent Auditors Report for the year ended In addition, 25,000 new Ordinary Shares were issued at a 31 March 2015. premium of 0.7% to the prevailing cum income NAV per share at the time of issue.
Business and Status of the Company Since the year end 437,331 Ordinary Shares were bought back The Company is registered as a public limited company in into treasury at an average discount of 6.4% to the prevailing England Registered Number 3023689 and is an investment ex income NAV per share.
32,500 of these shares were company within the terms of Section 833 of the Companies subsequently reissued from treasury at an average discount of Act 2006 the Act.
Its shares are premium listed on the 2.8% to the prevailing cum income NAV per share at the time Official List of the UK Listing Authority and traded on the of issue, resulting in a net gain to the Company of 20,000. main market of the London Stock Exchange, which is a regulated market as defined in Section 1173 of the Act.
Voting Rights in the Companys shares The Company has received approval from HM Revenue & Details of the voting rights in the Companys shares at the Customs as an authorised investment trust under Sections date of this Annual Report are given in note 9 to the Notice of 1158 and 1159 of the Corporation Tax Act 2010 CTA 2010 Annual General Meeting on page 77. effective for all years commencing after 1 April 2012.
This approval is subject to there being no subsequent enquiry Subscription Shares under corporation tax self-assessment.
In the opinion of the The Companys Subscription Shares were allotted on Directors, the Company continues to direct its affairs so as 4 September 2009 to Ordinary Shareholders on the register at to enable it to qualify for such approval.
5.00 p. m. on 3 September 2009, by way of a bonus issue on the basis of one Subscription Share for every five Ordinary Continuation of the Company Shares held at that date.
This resulted in the issue of A resolution was passed at the Annual General Meeting held 9,730,960 Subscription Shares.
in 2014 that the Company should continue as an investment As each Subscription Share conferred the right, but not the trust for a further five year period.
In accordance with the obligation, to subscribe for one Ordinary Share, the Directors Companys Articles of Association, shareholders will have an considered that this met the criteria for the Subscription opportunity to vote on the continuation of the Company at the Shares to be classified as equity in accordance with FRS 25.
2019 Annual General Meeting and every five years thereafter.
The subscription right conferred by each Subscription Share Results and Dividends could be exercised on each of 31 October, 31 January, The results attributable to shareholders for the year and the 30 April and 31 July or if such date was not a business day, transfer to reserves are shown on page 48.
Details of the on the next following business day between and including Companys dividend record can be found on page 2.
Capital Structure Over the life of the Subscription Shares the subscription price The Companys capital structure is composed solely of Ordinary stepped up from 614 pence per share from 31 October 2009 to Shares.
The Companys Subscription Shares expired on 31 July 31 July 2010, to 638 pence per share from 1 August 2010 to 2014.
31 July 2012 and finally to the final price of 699 pence per share that applied until 31 July 2014, the date of expiry of the Ordinary Shares Subscription Shares.
During the year 1,860,969 Ordinary Shares were allotted by These subscription prices represented premia of 1%, 5% and the Company as a result of holders of the Subscription Shares 15% respectively to the published unaudited net asset value exercising their subscription rights raising 13,008,000. per Ordinary Share as at 5.00 p. m. on 3 September 2009 During the year under review, 286,096 Ordinary Shares were including revenue, which was 607.44 pence per share.
bought back by the Company to be held in treasury at an A full description of the Subscription Shares and their terms average discount of 7.6% to the prevailing ex income NAV per was publicised via a prospectus issued to existing Ordinary share.
These shares were then reissued from treasury during Shareholders on 11 August 2009, available on the Companys the year at an average discount of 2.5% to the prevailing website.
Worldwide Healthcare Trust PLC 25 Annual Report for the year ended 31 March 2015 235876 Finsbury WWH pp23-pp29new 03 07 2015 15:04 Page 26 Substantial Interests in Share Capital The Company was aware of the following substantial interests in the voting rights of the Company as at 24 June 2015, the latest practicable date before publication of the Annual Report: 24 June 2015 31 March 2015 Number of % of issued Number of % of issued Shareholder shares share capital shares share capital Investec Wealth & Investment 5,552,472 11.6 5,509,664 11.4 Alliance Trust Savings 2,378,965 5.0 2,388,583 5.0 Rathbones 2,330,783 4.9 2,493,253 5.2 Charles Stanley, Stockbrokers 1,921,609 4.0 1,997,390 4.2 Brewin Dolphin, Stockbrokers 1,796,717 3.8 1,887,022 3.9 Spiers & Jeffrey, Stockbrokers 1,788,697 3.7 1,784,582 3.7 Hargreaves Lansdown 1,779,499 3.7 1,779,435 3.7 Smith & Williamson 1,447,725 3.0 1,484,841 3.1 As at 31 March 2015 the Company had 48,178,080 shares in issue.
As at 24 June 2015 the Company had 47,773,249 shares in issue excluding treasury shares.
capitalisation in excess of 500 million, plus a fixed amount Beneficial Owners of Shares Information Rights equal to 57,500 per annum, and a performance fee as set Beneficial owners of shares who have been nominated by out in the Performance Fee section below.
the registered holder of those shares to receive information rights under section 146 of the Companies Act 2006 are The notice period on the AIFM Agreement with Frostrow is required to direct all communications to the registered 12 months, termination can be initiated by either party.
holder of their shares rather than to the Companys registrar, Capita Asset Services, or to the Company directly.
Portfolio Management Agreement Under the AIFM Agreement Frostrow has delegated the Significant Agreements portfolio management function to OrbiMed, under a new Details of the services provided under these agreements are portfolio management agreement between it, the Company included in the Strategic Report on page 19. and Frostrow the Portfolio Management Agreement.
The Portfolio Management Agreement terminated and replaced Alternative Investment Fund Management the then existing investment management agreement Agreement between the Company and OrbiMed the Existing IMA.
The The Board announced in 2014 that the Company had adjusted its Portfolio Management Agreement is based on the Existing operational arrangements in order to comply with the AIFMD IMA and differs only to the extent necessary to ensure that and had appointed Frostrow as the designated AIFM for the the relationship between the Company, OrbiMed and Company on the terms and subject to the conditions of the Frostrow is compliant with the requirements of the AIFMD.
alternative investment fund management agreement between OrbiMed receives a periodic fee equal to 0.65% p. a. of the the Company and Frostrow the AIFM Agreement.
This Companys NAV and a performance fee as set out in the agreement terminated and replaced the then existing Performance Fee section below.
Its agreement with the management, administrative and secretarial services agreement Company may be terminated by either party giving notice of between the Company and Frostrow the Existing Management not less than 12 months.
The AIFM Agreement is based on the Existing Management Agreement and differs only to the extent necessary Performance Fees to ensure that the relationship between the Company and Dependent on the level of long-term outperformance of the Frostrow is compliant with the requirements of AIFMD.
Company, OrbiMed and Frostrow are entitled to a Under the terms of the AIFM Agreement Frostrow receives a performance fee.
The performance fee is calculated by periodic fee equal to 0.30% per annum of the Companys reference to the amount by which the Companys NAV market capitalisation up to 150 million, 0.20% per annum performance has outperformed the Benchmark see page 2 of the market capitalisation in excess of 150 million and up for details of the Benchmark.
to 500 million, and 0.125% per annum of the market Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2015 26 235876 Finsbury WWH pp23-pp29new 03 07 2015 12:33 Page 27 2 Governance Report of the Directors continued The fee is calculated quarterly by comparing the cumulative custody agreement between the Company and Goldman performance of the Companys NAV with the cumulative Sachs & Co. was terminated.
performance of the Benchmark since the launch of the Under the terms of the Depositary Agreement the Company Company in 1995.
The performance fee amounts to 16.5% of any has agreed to pay the Depositary a fee calculated at 1.75bp outperformance over the Benchmark, OrbiMed receiving 15% on net assets up to 150 million, 1.50 bps on net assets and Frostrow receiving 1.5% respectively.
Provision is also made between 150 million and 300 million 1.00bps on net assets within the daily NAV per share calculation as required and in between 300 million and 500 million and 0.50bps on net accordance with generally accepted accounting standards.
The Depositary has delegated the In order to ensure that only sustained outperformance is custody and safekeeping of the Companys assets to J. P. rewarded, at each quarterly calculation date any performance Morgan Clearing Corp the Prime Broker pursuant to a fee payable is based on the lower of: delegation agreement between the Company, Frostrow, the Depositary and the Prime Broker the Delegation i The cumulative outperformance of the portfolio over the Agreement.
Benchmark as at the quarter end date: and The Delegation Agreement transfers the Depositarys liability ii The cumulative outperformance of the portfolio over the for the loss of the Companys financial instruments held in Benchmark as at the corresponding quarter end date in the custody by the Prime Broker to the Prime Broker in previous year.
The Company has consented to The effect of this is that outperformance has to be maintained the transfer and reuse of its assets by the Prime Broker for a twelve month period before it is paid.
known as rehypothecation in accordance with the terms of In addition, a performance fee only becomes payable to the an institutional account agreement between the Company, extent that the cumulative outperformance gives rise to a total the Prime Broker and certain other J. P. Morgan entities as fee greater than the total of all performance fees paid to date.
See page 21 for further details.
As described in the Chairmans statement, on page 3, a Prime Brokerage Agreement provision for potential future performance fee payments The Company appointed J. P. Morgan Clearing Corp the amounting to 16.7m has been included in the performance Prime Broker on the terms and subject to the conditions fee accrual of 18.9m as detailed in note 11 on page 60.
This of the prime brokerage agreement between the Company, compares to a corresponding provision as at 31 March 2014 Frostrow and the Depositary the Prime Brokerage of 8.8m which, as a result of the continued outperformance Agreement.
The Prime Broker receives interest on the in the periods up to 31 March 2015, became payable in full drawn overdraft as detailed in note 11 on page 60. during this year.
The Prime Broker is a registered broker-dealer and is The reason for the significant increase in this provision when regulated by the United States Securities and Exchange compared to prior years is the continued substantial Commission.
outperformance that has been generated for the Company when compared to the Benchmark, coupled with the Greenhouse Gas Emissions consistency of, and length of time over which, the The Company has no greenhouse gas emissions to report outperformance has been achieved.
The amount of the from its operations, nor does it have responsibility for any 16.7m provision that may become payable is dependent on other emissions producing sources under the Companies the performance that is actually achieved in the year ending Act 2006 Strategic Report and Directors Reports 31 March 2016.
The maximum amount payable by 31 March Regulations 2013.
2016, in the event that the outperformance achieved as at 31 March 2015 is maintained, is 16.7m.
Audit Tender Depositary Agreement As reported in the Companys 2014 annual report, following The Company appointed J. P. Morgan Europe Limited the a tender process held in April 2014  Depositary as its Depositary in accordance with AIFMD on LLP PwC were recommended by the Audit Committee to the terms and subject to the conditions of the Depositary be appointed as Auditors to the Company with effect from agreement between the Company, Frostrow and the the conclusion of the Companys Annual General Meeting Depositary the Depositary Agreement.
The previous held on 14 July 2014.
Worldwide Healthcare Trust PLC 27 Annual Report for the year ended 31 March 2015 235876 Finsbury WWH pp23-pp29new 03 07 2015 12:33 Page 28 Directors & Officers Liability Insurance Cover Directors & officers liability insurance cover was maintained by the Company during the year ended 31 March 2015.
It is intended that this policy will continue for the year ending 31 March 2016 and subsequent years.
Directors Indemnities During the year under review and to the date of this report, indemnities were in force between the Company and each of its Directors under which the Company has agreed to indemnify each Director, to the extent permitted by law, in respect of certain liabilities incurred as a result of carrying out his or her role as a Director of the Company.
The Directors are also indemnified against the costs of defending any criminal or civil proceedings or any claim by the Company or a regulator as they are incurred provided that where the defence is unsuccessful the Director must repay those defence costs to the Company.
The indemnities are qualifying third party indemnity provisions for the purposes of the Companies Act 2006.
A copy of each deed of indemnity is available for inspection at the Companys registered office during normal business hours and will be available for inspection at the Annual General Meeting.
By order of the Board Frostrow Capital LLP Company Secretary 24 June 2015 Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2015 28
